53-03-2

Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least
Eye Contact
15 minutes. Cold water may be used. WARM water MUST be used. Get medical attention if irritation occurs.
Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops.
Skin Contact
Serious Skin ContactNot available.
InhalationIf inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get
medical attention.
Not available.
Serious Inhalation
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an
Ingestion
unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight
clothing such as a collar, tie, belt or waistband.
Not available.
Serious Ingestion

---

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Not available.
Flash Points
Not available.
Flammable Limits
These products are carbon oxides (CO, CO2).
Products of Combustion
Fire Hazards in Presence of Slightly flammable to flammable in presence of heat.
Various Substances
Risks of explosion of the product in presence of mechanical impact: Not available.
Explosion Hazards in
Slightly explosive in presence of open flames and sparks.
Presence of Various
Substances
SMALL FIRE: Use DRY chemical powder.
Fire Fighting Media
LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
and Instructions
Material in powder form, capable of creating a dust explosion. As with most organic solids, fire is possible at elevated
Special Remarks on
temperatures
Fire Hazards
Fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust
Special Remarks on
explosion hazard.
Explosion Hazards

---

Section 6. Accidental Release Measures
Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading
Small Spill
water on the contaminated surface and dispose of according to local and regional authority requirements.
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on
Large Spill
the contaminated surface and allow to evacuate through the sanitary system.
Prednisone

---

Section 7. Handling and Storage
Keep away from heat. Keep away from sources of ignition. Ground all equipment containing material. Do not
Precautions
breathe dust. Wear suitable protective clothing. If you feel unwell, seek medical attention and show the label when
possible. Keep away from incompatibles such as oxidizing agents.
Keep container tightly closed. Keep container in a cool, well-ventilated area. Material should be stored at a
Storage
temperature less than 40 deg C., preferably between 15-30 deg. C.

---

Section 8. Exposure Controls/Personal Protection
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
Engineering Controls
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal ProtectionSafety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used to
avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE
of a Large Spill
handling this product.
Not available.
Exposure Limits

---

Section 9. Physical and Chemical Properties
Solid. (Solid crystalline powder.)Odorless.
Physical state andO dor
appearance
Bitter. Aftertaste.
Taste
358.43 g/mole
Molecular Weight
White or nearly white.
Color
Not available.
pH (1% soln/water)
Not available.
Boiling Point
Decomposition temperature: 230°C (446°F) - 235 C.
Melting Point
Not available.
Critical Temperature
Not available.
Specific Gravity
Not applicable.
Vapor Pressure
Not available.
Vapor Density
Not available.
Volatility
Not available.
Odor Threshold
Not available.
Water/Oil Dist. Coeff.
Not available.
Ionicity (in Water)
Not available.
Dispersion Properties
Very slightly soluble in cold water.
Solubility
Slightly soluble in methanol.
1 g soluble in 150 ml alcohol.
1 g soluble in 200 ml chloroform.

---

Section 10. Stability and Reactivity Data
The product is stable.
Stability
Not available.
Instability Temperature
Conditions of Instability Excess heat, incompatible materials.
Incompatibility with various Reactive with oxidizing agents.
substances
Prednisone
Non-corrosive in presence of glass.
Corrosivity
Not available.
Special Remarks on
Reactivity
Not available.
Special Remarks on
Corrosivity
Will not occur.
Polymerization

---

Section 11. Toxicological Information
Inhalation. Ingestion.
Routes of Entry
Toxicity to AnimalsLD50: Not available.
LC50: Not available.
Chronic Effects on Humans CARCINOGENIC EFFECTS: 3 (Not classifiable for human.) by IARC.
MUTAGENIC EFFECTS: Mutagenic for bacteria and/or yeast.
Slightly hazardous in case of skin contact (irritant), of ingestion, of inhalation.
Other Toxic Effects on
Humans
Not available.
Special Remarks on
Toxicity to Animals
May cause adverse reproductive effects and cancer based on animal test data.
Special Remarks on
Chronic Effects on Humans May affect genetic material (mutagenic).
Human: small amount excreted in maternal milk.
Acute Potential Health Effects:
Special Remarks on other
Skin: May cause skin irritation. May cause skin sensitization, an allergic reaction.
Toxic Effects on Humans
Eyes: May cause eye irritation.
Inhalation: May cause respiratory tract irritation.
Ingestion: May cause gastritis with nausea, vomiting, abdominal distention, ulcerative esophagitis, increased
sweating. May affect metabolism and cause disturbance of electrolyte balance which is manifest in the retention of
sodium and water, with edema and hypertension, and in the increased excretion of potassium with the possibility of
hypokalaemic alkalosis. Cardiac faillure may be induced in sensitive individuals.
Chronic Potential Health Effects:
Skin: Prolonged or repeated skin contact may cause sensitization, an allergic reaction.
Eyes: Prolonged contact with eyes may affect vision (cataracts)
Inhalation/Ingestion: May cause anaphylaxis, an allergic reaction. Prolonged or repeated inhalation or ingestion of
corticosteroids may also cause thinning of the skin, inpaired wound healing and other dermatologic reactions
(erythema, petechiae and ecchymoses).
Ingestion: Prolonged or repeated ingestion of corticosteroids may cause nausea, vomiting, abdominal distention,
peptic ulcer with possible perforation and hemorrhage, possible hypersensitization, swelling of the feet and lower legs
due to electrolyte imbalance and sodium retention, irregular hearbeat, acute adrenal insufficiency, osteoporosis,
muscle weakness, loss of muscle mass, vertebral compression fractures, pathologic fracture of long bones, aseptic
necrosis of femoral and humeral heads, effect glucose tolerance (causing decreased carbohydrate tolerance resulting
in manifestations of latent Diabetes melliltus, increased requirements for insulin or oral hypoglycemifcagents in
diabetes), the liver, pancreas (pancreatitis), eyes/vision (cataracts, glaucoma, increased intraocular pressure),
behavior/central nervous system/nervous system (mental disturbances such as psychosis, euphoria, depression, vertigo,
headache, convulsions, increased intracranial pressure with papilledema). It may also effect the immune system
(immunosuppressant). Repeated large doses of corticosteroids may produce Cushingoid symptoms typical of
hyperactivity of the adrenal cortex, with moon-face, sometimes hirsutism, buffalo hump, flushing, increased bruising,
ecchymoses, striae, and acne.
Medical Conditions Aggravated by Exposure: Hypersensivity to material, ocular herpes simplex, active alcoholism,
AIDS or HIV infection, heart disease or hypertension, diabetes mellitus, myasthenia gravis, impaired kidney or liver
function, esophagitis, gastritis or peptic ulcer, chickenpox or measles (including recent exposure), recent intestinal
surgery, tuberculosis, and system fungal infections.
Note: The above information came from Physicians GenRx - Drug Information, 1995 or was extrapolated from
information for Corticosteriods found in a reference called Martindale.
Prednisone

---

Section 12. Ecological Information
Not available.
Ecotoxicity
Not available.
BOD5 and COD
Products of Biodegradation Possibly hazardous short term degradation products are not likely. However, long term degradation products may
arise.
The product itself and its products of degradation are not toxic.
Toxicity of the Products
of Biodegradation
Not available.
Special Remarks on the
Products of Biodegradation

---

Section 13. Disposal Considerations
Waste must be disposed of in accordance with federal, state and local environmental control
Waste Disposal
regulations.

---

Section 14. Transport Information
Not a DOT controlled material (United States).
DO T Cl assi fi cati on
Not applicable.
Identification
Not applicable.
Special Provisions for
Transport
DO T (Pi ctograms)

---

Section 15. Other Regulatory Information and Pictograms
New Jersey: Prednisone
Federal and State
TSCA 8(b) inventory: Prednisone
Regulations
California prop. 65: This product contains the following ingredients for which the State of California has found to
California
cause cancer which would require a warning under the statute: No products were found.
Proposition 65
Warnings
California prop. 65: This product contains the following ingredients for which the State of California has found to
cause birth defects which would require a warning under the statute: No products were found.
EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances (EINECS No.
Other Regulations
200-160-3).
Canada: Listed on Canadian Non-Domestic Substance List (NDSL).
China: Not listed on National Inventory.
Japan: Listed on National Inventory (ENCS).
Korea: Listed on National Inventory (KECI).
Philippines: Not listed on National Inventory (PICCS).
Australia: Listed on AICS.
WHMIS (Canada) Not controlled under WHMIS (Canada).
Other Classifications
Not availableNot applicable.
DSCL (EEC)
Health Hazard
HMIS (U.S.A.)1 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
1 0 Reactivity
Health
Reactivity0
Specific hazard
Personal Protection
E
Prednisone
WHMIS (Canada)
(Pictograms)
DSCL (Europe)
(Pictograms)
TDG(Canada)
(Pictograms)
ADR (Europe)
(Pictograms)
Protective Equipment
Gloves.
Lab coat.
Dust respirator. Be sure to use an
approved/certified respirator or equivalent.
Prednisone
CALL (310) 516-8000
Notice to Reader
All chemicals may pose unknown hazards and should be used withcaution. This Material Safety Data Sheet (MSDS) applies only to the material as packaged. If this product is combined with other materials,
deteriorates, or becomes contaminated, it may pose hazards not mentioned inthis MSDS. It shall be the user's responsibility to develop proper methods of handling and personal protection based onthe actual

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

MOLECULAR FORMULA :

C21-H26-O5

MOLECULAR WEIGHT :

358.47

WISWESSER LINE NOTATION :

L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Human - woman

DOSE/DURATION :

2400 ug/kg/2D-I

TOXIC EFFECTS :

Peripheral Nerve and Sensation - sensory change involving peripheral nerve

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Human - man

DOSE/DURATION :

857 ug/kg

TOXIC EFFECTS :

Peripheral Nerve and Sensation - sensory change involving peripheral nerve

TYPE OF TEST :

LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Human - man

DOSE/DURATION :

400 ug/kg

TOXIC EFFECTS :

Skin and Appendages - dermatitis, other (after systemic exposure)

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Unreported

SPECIES OBSERVED :

Human - woman

DOSE/DURATION :

113 mg/kg

TOXIC EFFECTS :

Blood - hemorrhage Skin and Appendages - dermatitis, other (after systemic exposure)

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

135 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Subcutaneous

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

101 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intramuscular

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

600 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

860 mg/kg/26W-I

TOXIC EFFECTS :

Tumorigenic - equivocal tumorigenic agent by RTECS criteria Endocrine - tumors Skin and Appendages - tumors

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Subcutaneous

DOSE :

24 mg/kg

SEX/DURATION :

female 13-18 day(s) after conception

TOXIC EFFECTS :

Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral

MUTATION DATA

TYPE OF TEST :

Mutation in microorganisms

TEST SYSTEM :

Bacteria - Salmonella typhimurium

DOSE/DURATION :

333 ug/plate

REFERENCE :

ENMUDM Environmental Mutagenesis. (New York, NY) V.1-9, 1979-87. For publisher information, see EMMUEG. Volume(issue)/page/year: 5(Suppl 1),3,1983 *** REVIEWS *** IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,293,1981 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,293,1981 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,326,1987 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 17,85,1980 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80494 No. of Facilities: 68 (estimated) No. of Industries: 1 No. of Occupations: 6 No. of Employees: 2770 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80494 No. of Facilities: 45 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 1266 (estimated) No. of Female Employees: 725 (estimated)